According to a new study, patients with type 2 diabetes who are not overweight and have had the disease for less than ten years may benefit from therapy based on transplantation of mesenchymal stem cells derived from their own bone marrow.
A team of researchers led by endocrinologists and biomedical engineers from the University of Washington School of Medicine in St. Louis and Cornell University has successfully demonstrated the possibility of implanting β-cells in diabetic mice using a miniature device. After the transplant, the cells secrete insulin in response to blood sugar levels and do not require immunosuppressants.
Scientists from the United States have reported a breakthrough in the field of medicine – the creation of an embryo that is partly human and partly monkey. However, researchers talk about serious ethical issues that need to be addressed before the discovery can be used in practice.
The new stem cell therapy will make diabetes-related amputations a thing of the past, according to the results of the phase 1 clinical trial. The trial involved administering a cell preparation containing adult mesenchymal stem cells (MSCs) derived from the patients’ own fat to patients with type 2 diabetes with diabetic foot ulcers (DFU). The results showed that the treatment stimulated the regeneration of the blood vessels surrounding the DFUs and accelerated healing. However, there were no serious side effects.
Researchers have found one of the reasons why more than 50% of people with type 2 diabetes die from complications from cardiovascular disease. And more importantly, they may have found a therapeutic approach based on stem cell activation that solves this problem.
Scientists from the Helmholtz Zentrum München, Germany, were able to describe in detail the pathways of intestinal stem cell differentiation. Understanding this process will help create specific early treatments for endocrine dysfunction and may also be a promising regenerative approach to diabetes therapy.
Using stem cells, researchers at the Salk Institute for the first time created clusters of pancreatic cells that produce human insulin and are able to avoid rejection by the immune system. After transplantation into mice, the clusters effectively controlled blood glucose levels throughout the life of the animals without the use of immunosuppressants.
A new study has demonstrated the promise of a revolutionary approach in the treatment of trophic foot ulcers associated with diabetes. Scientists have shown for the first time that a bioengineered scaffold composed of human mesenchymal stem cells (MSCs) combined with a drug commonly used to treat glaucoma improved healing and reduced wound inflammation in diabetic mice by as much as 75% compared to controls.
The results obtained by researchers from the University of Washington University School of Medicine in St. Louis showed that the CRISPR/Cas9 technology may be promising as a treatment for diabetes, especially forms caused by a single gene mutation, and may also be used in the future for some patients with more common forms diabetes, such as type 1 and type 2.
The researchers efficiently convert human stem cells into insulin-producing cells, which helped stabilize blood sugar and functionally cure diabetes for nine months after transplantation to mice.
Stem cell therapy
- The combination of gene therapy and stem cell therapy has shown long-term success in treating rare skin disease30.12.2021 - 01:34
- Stem cells use fat to fight infection18.12.2021 - 01:04
- Xenobots created a year ago from stem cells have learned to reproduce12.12.2021 - 00:41
- The therapeutic potential of mesenchymal stem cell vesicles could be increased tenfold05.12.2021 - 21:06
Clinic in Kyiv:
+380 67 549 11 61
+380 97 409 91 01
Our representative in Italy:
+99 559 761 43 34
+99 559 996 15 15
Clinic in Prague:
+420 720 087 788
+420 720 097 788